27. ACMG/CGC technical laboratory standards for interpretation and reporting of acquired copy number abnormalities (CNAs) and copy-neutral loss of heterozygosity (CN-LOH) in neoplastic disorders

Gordana Raca,Jaclyn Biegel,Linda Cooley,Adrian Dubuc,Betsy Hirsch,Vanessa Horner,Scott Newman,Lina Shao,Daynna Wolff,Fady Mikhail

doi:10.1016/j.cancergen.2019.04.033

27. ACMG/CGC technical laboratory standards for interpretation and reporting of acquired copy number abnormalities (CNAs) and copy-neutral loss of heterozygosity (CN-LOH) in neoplastic disorders

Gordana Raca, Jaclyn Biegel + Show 8 more

https://doi.org/10.1016/j.cancergen.2019.04.033

Copy DOI

Journal: Cancer genetics	Publication Date: Apr 1, 2019
Citations: 2

Affiliation: Children's Hospital of Los Angeles, University of Missouri–Kansas City, Brigham and Women's Hospital, University of Minnesota, University of Wisconsin–Madison, St. Jude Children's Research Hospital, University of Michigan–Ann Arbor, Medical University of South Carolina, University of Alabama at Birmingham

#Copy-neutral Loss Of Heterozygosity Regions #American College Of Medical Genetics + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

With the expanded clinical use of Chromosome Microarray Analysis (CMA) to detect diagnostic, prognostic and therapeutic markers in cancer, there is a growing need for standardized, objective and evidence-based interpretation and reporting of CMA findings. Here we present the classification and reporting recommendations for acquired CNAs and CN-LOH regions in neoplastic disorders, created through collaboration between the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC).

Full Text